ScinoPharm Taiwan, Ltd. (TPE:1789)
Taiwan
· Delayed Price · Currency is TWD 23.10
+0.25 (1.09%)
Feb 27, 2025, 1:30 PM CST
ScinoPharm Taiwan Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 3,406 | 3,186 | 3,264 | 2,762 | 3,083 | Upgrade
|
| Revenue Growth (YoY) | 6.91% | -2.39% | 18.16% | -10.40% | 6.57% | Upgrade
|
| Cost of Revenue | 2,106 | 1,970 | 2,013 | 1,482 | 1,765 | Upgrade
|
| Gross Profit | 1,300 | 1,216 | 1,251 | 1,280 | 1,317 | Upgrade
|
| Selling, General & Admin | 518.14 | 543.83 | 573.88 | 685.79 | 696.32 | Upgrade
|
| Research & Development | 459.36 | 357.74 | 271.26 | 305.95 | 245.63 | Upgrade
|
| Operating Expenses | 977.5 | 901.5 | 845.28 | 991.87 | 941.74 | Upgrade
|
| Operating Income | 322.71 | 314.49 | 405.5 | 288.62 | 375.72 | Upgrade
|
| Interest Expense | -8.08 | -9.15 | -7.91 | -6.55 | -15.17 | Upgrade
|
| Interest & Investment Income | 61.52 | 53.63 | 22.12 | 19.38 | 27.41 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -9.4 | 41.27 | -7.91 | -31.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 38.54 | -0.31 | -22.88 | 7.63 | 0.68 | Upgrade
|
| EBT Excluding Unusual Items | 414.69 | 349.26 | 438.09 | 301.17 | 357.38 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.42 | -0.76 | -0.27 | -3.16 | Upgrade
|
| Asset Writedown | -1.67 | 0 | 0.63 | 1.38 | 4.28 | Upgrade
|
| Pretax Income | 413.02 | 348.84 | 437.96 | 302.29 | 358.51 | Upgrade
|
| Income Tax Expense | 73.67 | 61.78 | 84.74 | 58.82 | 76.44 | Upgrade
|
| Net Income | 339.35 | 287.06 | 353.22 | 243.47 | 282.07 | Upgrade
|
| Net Income to Common | 339.35 | 287.06 | 353.22 | 243.47 | 282.07 | Upgrade
|
| Net Income Growth | 18.22% | -18.73% | 45.08% | -13.68% | 30.19% | Upgrade
|
| Shares Outstanding (Basic) | 789 | 791 | 791 | 791 | 791 | Upgrade
|
| Shares Outstanding (Diluted) | 789 | 792 | 793 | 792 | 792 | Upgrade
|
| Shares Change (YoY) | -0.40% | -0.04% | 0.05% | 0.01% | 0.01% | Upgrade
|
| EPS (Basic) | 0.43 | 0.36 | 0.45 | 0.31 | 0.36 | Upgrade
|
| EPS (Diluted) | 0.43 | 0.36 | 0.45 | 0.31 | 0.36 | Upgrade
|
| EPS Growth | 19.44% | -19.41% | 45.08% | -13.68% | 32.12% | Upgrade
|
| Free Cash Flow | 470.74 | -37.3 | 530.51 | 195.4 | 766.34 | Upgrade
|
| Free Cash Flow Per Share | 0.60 | -0.05 | 0.67 | 0.25 | 0.97 | Upgrade
|
| Dividend Per Share | - | 0.300 | 0.360 | 0.480 | 0.500 | Upgrade
|
| Dividend Growth | - | -16.67% | -25.00% | -4.00% | 85.19% | Upgrade
|
| Gross Margin | 38.17% | 38.17% | 38.32% | 46.36% | 42.73% | Upgrade
|
| Operating Margin | 9.47% | 9.87% | 12.42% | 10.45% | 12.19% | Upgrade
|
| Profit Margin | 9.96% | 9.01% | 10.82% | 8.81% | 9.15% | Upgrade
|
| Free Cash Flow Margin | 13.82% | -1.17% | 16.25% | 7.07% | 24.86% | Upgrade
|
| EBITDA | 810.99 | 759.82 | 829.1 | 655.41 | 754.38 | Upgrade
|
| EBITDA Margin | 23.81% | 23.85% | 25.40% | 23.73% | 24.47% | Upgrade
|
| D&A For EBITDA | 488.28 | 445.33 | 423.61 | 366.79 | 378.66 | Upgrade
|
| EBIT | 322.71 | 314.49 | 405.5 | 288.62 | 375.72 | Upgrade
|
| EBIT Margin | 9.47% | 9.87% | 12.42% | 10.45% | 12.19% | Upgrade
|
| Effective Tax Rate | 17.84% | 17.71% | 19.35% | 19.46% | 21.32% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.